IDEAYA Biosciences, Inc. (NASDAQ: IDYA) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $53.00 to $46.00. They now have a "buy" rating on the stock.
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $52.00 price target on the stock.
IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
Delphia Therapeutics Launches to Pioneer a New Field of Cancer Medicines: Activation Lethality [Yahoo! Finance]
IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event